Theragenics rejects Eckert & Ziegler's $74M takeover bid

Eckert & Ziegler of Berlin has submitted a non-binding proposal to the board of directors of the Buford, Ga.-based Theragenics to acquire, either directly or through IBt Bebig, all the outstanding shares of Theragenics for $2.20 per share, in cash. However, Theragenics has been unwilling to engage in takeover discussions, according to Eckert & Ziegler.

The non-binding offer, made on Feb. 8 and rejected by Theragenics on March 11, and was reiterated in a letter sent on March 17 to Theragenics' board of directors. 

The offer represented a total equity value of approximately $74 million and a premium of 38.4 percent more than Theragenics' closing stock price on March 16. The offer also represented a premium of 15.8 percent over the 52-week high trading price of Theragenics stock, according to Eckert & Ziegler.


Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.